Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422654 · ClinicalTrials.gov registry record · Phase 1
Taste Evaluation of Different Liquid Formulations With Eliglustat
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02422654 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 8 participants.
The verdict
NCT02422654, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Primary Objective: The purpose of this study is to assess the palatability of eliglustat prototype liquid formulations in healthy subjects.
Interventions
- DRUG eliglustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02422654
The ClinicalTrials.gov registry entry for NCT02422654 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eliglustat is the first listed.
NCT02422654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02422654 about?
NCT02422654 is a clinical study titled "Taste Evaluation of Different Liquid Formulations With Eliglustat". Primary Objective: The purpose of this study is to assess the palatability of eliglustat prototype liquid formulations in healthy subjects.
What is the current status of trial NCT02422654?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-04. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02422654?
The interventions under investigation include: eliglustat (DRUG).
Who is sponsoring clinical trial NCT02422654?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.